Samay
Mountain View
About Samay
COPD will cost $61 billion per year by 2029, but no technologies can evaluate lung function from home, leaving patients and doctors to rely on questionnaires. Samay will disrupt the remote diagnostic market just as Dexcom did with Diabetes and iRhythm with cardiac arrhythmias. Our chest patches use a patented technology that diagnoses COPD with 90% accuracy and detects exacerbation biomarkers with 83% accuracy, passively. We're building an AI-assisted management and diagnostic platform to accompany patients and doctors throughout the care continuum, from exacerbation detection to determining effective therapies for more personalized care, all from home.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $5.2M
- Funding stage: Seed
- Last round: Grant (Oct 2024)
- Website: samayhealth.com
- Phone: [email protected]
Industries & Categories
Artificial Intelligence (AI), Health Diagnostics, Machine Learning, Medical Device, Wearables
Social Profiles
Canonical: https://fsome.com/organization/samay-31861 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.